The Role of Metoprolol and Enalapril in the Prevention of Doxorubicin-induced Cardiotoxicity in Lymphoma Patients

Georgakopoulos, Peter; Kyriakidis, Michael; Perpinia, Anastasia; Karavidas, Apostolos; Zimeras, Stelios; Mamalis, N.; Kouvela, Marousa; Charpidou, Andriani

doi:10.21873/anticanres.13769

Cited by 19 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A systematic review, by Zhang et al, in which seven studies were examined, concluded that enalapril was effective, although the need for further evidence was specified. [53][54][55][56]…”

Section: Angiotensin-converting Enzyme Inhibitors (Acei)mentioning

confidence: 99%

How to identify anthracycline-induced cardiotoxicity early and reduce its clinical impact in everyday practice

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A systematic review, by Zhang et al, in which seven studies were examined, concluded that enalapril was effective, although the need for further evidence was specified. [53][54][55][56]…”

Section: Angiotensin-converting Enzyme Inhibitors (Acei)mentioning

confidence: 99%

How to identify anthracycline-induced cardiotoxicity early and reduce its clinical impact in everyday practice

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In order to promote antitumor activity of chemotherapeutic agents, high doses of these agents are applied that substantially enhances side effects on other organs of body. Ototoxicity [9], hepatotoxicity [10], nephrotoxicity [11] and cardiotoxicity [12] are a few of adverse effects of chemotherapeutic agents.…”

Section: Introductionmentioning

confidence: 99%

Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity

et al. 2020

View full text Add to dashboard Cite

Doxorubicin (DOX) is a well-known chemotherapeutic agent extensively applied in the field of cancer therapy. However, similar to other chemotherapeutic agents such as cisplatin, paclitaxel, docetaxel, etoposide and oxaliplatin, cancer cells are able to obtain chemoresistance that limits DOX efficacy. In respect to dose-dependent side effect of DOX, enhancing its dosage is not recommended for effective cancer chemotherapy. Therefore, different strategies have been considered for reversing DOX resistance and diminishing its side effects. Phytochemical are potential candidates in this case due to their great pharmacological activities. Curcumin is a potential antitumor phytochemical isolated from Curcuma longa with capacity of suppressing cancer metastasis and proliferation and affecting molecular pathways. Experiments have demonstrated the potential of curcumin for inhibiting chemoresistance by downregulating oncogene pathways such as MMP-2, TGF-β, EMT, PI3K/Akt, NF-κB and AP-1. Furthermore, coadministration of curcumin and DOX potentiates apoptosis induction in cancer cells. In light of this, nanoplatforms have been employed for codelivery of curcumin and DOX. This results in promoting the bioavailability and internalization of the aforementioned active compounds in cancer cells and, consequently, enhancing their antitumor activity. Noteworthy, curcumin has been applied for reducing adverse effects of DOX on normal cells and tissues via reducing inflammation, oxidative stress and apoptosis. The current review highlights the anticancer mechanism, side effects and codelivery of curcumin and DOX via nanovehicles.

show abstract

“…Carvedilol is a β-blocker with unique antioxidant properties and emerges as a strategy to prevent cardiotoxicity, but there are also clinical trials questioning its effectiveness. Some evidence suggested that antioxidants, rather than β-blocker, can prevent cardiotoxicity, but the antioxidant effect of carvedilol may not be sufficient in some cases [ 148 ]. In-depth study of acetylation will help to explore the impact of drugs on the occurrence and development of diseases from the perspective of molecular mechanisms, thereby promoting safer and more effective implementation of clinical trials.…”

Section: Discussionmentioning

confidence: 99%

Role of acetylation in doxorubicin-induced cardiotoxicity

Yang

Wang

et al. 2021

Redox Biology

View full text Add to dashboard Cite

As a potent chemotherapeutic agent, doxorubicin (DOX) is widely used for the treatment of a variety of cancers However, its clinical utility is limited by dose-dependent cardiotoxicity, and pathogenesis has traditionally been attributed to the formation of reactive oxygen species (ROS). Accordingly, the prevention of DOX-induced cardiotoxicity is an indispensable goal to optimize therapeutic regimens and reduce morbidity. Acetylation is an emerging and important epigenetic modification regulated by histone deacetylases (HDACs) and histone acetyltransferases (HATs). Despite extensive studies of the molecular basis and biological functions of acetylation, the application of acetylation as a therapeutic target for cardiotoxicity is in the initial stage, and further studies are required to clarify the complex acetylation network and improve the clinical management of cardiotoxicity. In this review, we summarize the pivotal functions of HDACs and HATs in DOX-induced oxidative stress, the underlying mechanisms, the contributions of noncoding RNAs (ncRNAs) and exercise-mediated deacetylases to cardiotoxicity. Furthermore, we describe research progress related to several important SIRT activators and HDAC inhibitors with potential clinical value for chemotherapy and cardiotoxicity. Collectively, a comprehensive understanding of specific roles and recent developments of acetylation in doxorubicin-induced cardiotoxicity will provide a basis for improved treatment outcomes in cancer and cardiovascular diseases.

show abstract

The Role of Metoprolol and Enalapril in the Prevention of Doxorubicin-induced Cardiotoxicity in Lymphoma Patients

Cited by 19 publications

References 0 publications

How to identify anthracycline-induced cardiotoxicity early and reduce its clinical impact in everyday practice

How to identify anthracycline-induced cardiotoxicity early and reduce its clinical impact in everyday practice

Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity

Role of acetylation in doxorubicin-induced cardiotoxicity

Contact Info

Product

Resources

About